Taofeek K. Owonikoko Md Phd

Taofeek Owonikoko, MD, PhD on Lung and Thyroid Cancers and Early Phase Drug Development

The Moss Report

Dr. Owonikoko on Standard of Care for SCLC

Winship Grand Rounds August 3, 2016: Taofeek Owonikoko, MD, PhD, MSCR

Winship Cancer Institute of Emory University

Dr Owonikoko on the Impact of the FDA Approval of Tarlatamab in ES-SCLC

Owonikoko: What it means to be a Black director of an NCI-designated cancer center

The Cancer Letter

owonikoko What is Immunotherapy

Winship Cancer Institute of Emory University

Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next?

PeerView Oncology

Assessing Advancements in Treatment Options for Small Cell Lung Cancer

Avoiding Needless Testing in NSCLC Treatment

Your Invitation to the 2021 ASCO Annual Meeting

Facilitating Progress in the Treatment of SCLC

PeerView Oncology

Progress on the Path to Improving Outcomes in the Treatment of SCLC

Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives

PeerView Oncology

Dr. Tauer on Arguments in Favor of and Against Biosimilars in Oncology

Lung cancer, lung bacteria or lung fungus?

Know The Cause Too! - Live with Doug Kaufmann

Doctor's Forum : Why Pituitary Tumors Are Important: ( by Dr. Tayo Ojo and Dr. Chiazor Onyia)

Lagoon Hospitals

Impact of the Microbiome on Immune Therapy in Kidney Cancer

GU Oncology Now

Dr. Ku on Role of Durvalumab in Gastric Cancer

Panel Q&A Session on Acquired Resistance with Drs. Reckamp & Owonikoko

GRACE - Global Resource for Advancing Cancer Education

Harnessing the Power of the Latest Clinical and Research Advances in SCLC

PeerView Oncology